Dr. Jin-Xiong She interview with NAD Research on the effects of IV NAD+ and NAD precursor supplementation

Chief Scientist and founder Dr. Jin-Xiong She sat down with NAD Research to discuss Jinfiniti’s intracellular NAD blood spot test and the longevity effects of IV NAD+ drip and NAD precursor supplementation.

NAD Research: Have you been able to observe, or have patients been able to report, improved clinical outcomes corresponding to their increased intracellular NAD levels?

Dr. She: Yes, we have an unbelievable and very positive patient response. Most people report improved energy, which is understandable since NAD is involved in ATP (adenosine triphosphate) production. Another common benefit is improved sleep because NAD regulates circadian genes. Mental clarity is another common one. Others are particular to individual health conditions.

NAD Research: Since most of NAD’s known functions take place within the cell, what do you suspect is the role of extracellular NAD?

Dr. She: Very good question. Most of the known functions of NAD are attributable to intracellular NAD. Nevertheless, extracellular NAD or circulating NAD may also be playing critical roles that are less well understood because we know that certain cell types—neuronal cells and immune cells—contain NAD receptors. We also know that NAD is a neurotransmitter and that it regulates immune cells and controls immune response.

In fact, I think the clinical benefits that we see from intravenous NAD infusions are due to circulating NAD—which explains why the clinical benefits are primarily addressing neurological problems, such as dementia and addiction, as well as certain infectious diseases like Lyme’s disease and more recently, COVID, or long COVID. The clinical benefits for these conditions are undeniable, although there are no published studies of large-scale clinical trials yet, as far as I know.

We just finished a clinical trial a week ago that demonstrated conclusively that intravenous NAD infusions do not increase intracellular NAD. Prior to that, we collected data from a number of patients who have had intravenous NAD infusions with no increase in intracellular NAD levels.

The evidence is very clear. There’s no gray zone. It’s black and white. So now we have to reconcile why intravenous NAD delivers the clinical outcomes in neurological function, but we don’t see an increase in intracellular NAD. The answer is that the results are being delivered by circulating NAD.

Read the full interview here on NAD Research.


This field is for validation purposes and should be left unchanged.
Already have an account? Log in here